Showing 521 - 540 results of 103,597 for search '(( 5 ((mg decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (we decrease)) ))', query time: 1.46s Refine Results
  1. 521

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  2. 522
  3. 523
  4. 524
  5. 525
  6. 526
  7. 527

    A decrease in circulating CXCR5+CD4+ Tfh cells is associated with HCC progression, and CXCR5+CD4+ Tfh cells are decreased in tumor regions. by Yiqiong Jia (692871)

    Published 2015
    “…<p>(A) The prevalence of CXCR5+CD4+ Tfh cells decreases with progressive stages in HCC. …”
  8. 528
  9. 529
  10. 530
  11. 531

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
  12. 532

    Serum concentrations of FGF23 at baseline and at week 40 in patients that achieved a serum phosphate concentration of <4.5 mg/dL and >4.5 mg/dL). by Cristian Rodelo-Haad (5607911)

    Published 2018
    “…Bars represent median and interquartile range. Serum iFGF23 decreased from 581.0 pg/mL (491.2–886.0) to 238.5 pg/mL (116.7–443.5) [median percent change of 63.8% (-75.2–5.40) in patients that achieved the target of phosphate <4.5 mg/dL. …”
  13. 533
  14. 534
  15. 535
  16. 536
  17. 537
  18. 538
  19. 539

    Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial by Seyyed Abbas Zojaji (5208589)

    Published 2022
    “…<div><p>Abstract Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. …”
  20. 540

    Insensitivity to the Spatial Repellent Action of Transfluthrin in <i>Aedes aegypti</i>: A Heritable Trait Associated with Decreased Insecticide Susceptibility by Joseph M. Wagman (725058)

    Published 2015
    “…Compared to the SR responder strain, the SR insensitive strain also demonstrated decreased susceptibility to transfluthrin toxicity in CDC bottle bioassays and a higher frequency of the V1016I<sup><i>kdr</i></sup> mutation.…”